Vaccines and compositions against Streptococcus pneumoniae

Patent metadata

Field	Value
Publication number	US-9393294-B2
Application number	US-201213355468-A
Country	US
Kind code	B2
Filing date	Jan 20, 2012
Priority date	Jan 20, 2011
Publication date	Jul 19, 2016
Grant date	Jul 19, 2016

Abstract

Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromized patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae . The antigens may be used therapeutically or prophylactically.

First claim

We claim:

1. A vaccine formulation comprising:
a pharmaceutically acceptable carrier;
an effective amount of an adjuvant;
a first isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 265, 266, or 268, or comprising the amino acid sequence of SEQ ID NO:265, 266, or 268 lacking 1-3 amino acids from the N-terminus, C-terminus, or both; and
a second isolated polypeptide comprising the amino acid sequence of SEQ ID NO:9 or 10, or comprising the amino acid sequence of SEQ ID NO:9 or 10 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.

2. The vaccine formulation of claim 1 , further comprising a third isolated polypeptide comprising the amino acid sequence of SEQ ID NO:6 or 7, or comprising the amino acid sequence of SEQ ID NO:6 or 7 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.

3. The vaccine formulation of claim 2 , wherein the third polypeptide consists of the amino acid sequence of SEQ ID NO:6.

4. The vaccine formulation of claim 2 , wherein the third polypeptide consists of the amino acid sequence of SEQ ID NO:7.

5. A vaccine formulation comprising:
a pharmaceutically acceptable carrier;
an effective amount of an adjuvant;
a first isolated polypeptide comprising the amino acid sequence of SEQ ID NO:265, 266, or 268, or comprising the amino acid sequence of SEQ ID NO:265, 266, or 268 lacking 1-3 amino acids from the N-terminus, C-terminus, or both; and
a second isolated polypeptide comprising the amino acid sequence of SEQ ID NO:6 or 7, or comprising the amino acid sequence of SEQ ID NO:6 or 7 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.

6. The vaccine formulation of claim 1 or 5 , wherein the first polypeptide consists of the amino acid sequence of SEQ ID NO:265.

7. The vaccine formulation of claim 1 or 5 , wherein the first polypeptide consists of the amino acid sequence of SEQ ID NO:266.

8. The vaccine formulation of claim 1 or 5 , wherein the first polypeptide consists of the amino acid sequence of SEQ ID NO:268.

9. The vaccine formulation of claim 1 , wherein the second polypeptide consists of the amino acid sequence of SEQ ID NO:9.

10. The vaccine formulation of claim 1 or 5 , wherein one or more polypeptides are conjugated to an immunogenic carrier.

11. The vaccine formulation of claim 1 or 5 , which comprises at least one lipidated polypeptide.

12. The vaccine formulation of claim 5 , wherein the second polypeptide consists of the amino acid sequence of SEQ ID NO:6.

13. The vaccine formulation of claim 5 , wherein the second polypeptide consists of the amino acid sequence of SEQ ID NO:7.

14. A vaccine formulation comprising:
a pharmaceutically acceptable carrier;
an effective amount of an adjuvant;
a first isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 265, 266, or 268 or comprising the amino acid sequence of SEQ ID NO:265, 266, or 268 lacking 1-3 amino acids from the N-terminus, C-terminus, or both;
a second isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 6 or comprising the amino acid sequence of SEQ ID NO:6 lacking 1-3 amino acids from the N-terminus, C-terminus, or both; and
a third isolated polypeptide comprising the amino acid sequence of SEQ ID NO:7 or comprising the amino acid sequence of SEQ ID NO:7 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.

15. The vaccine formulation of claim 14 , wherein the second polypeptide is lipidated.

16. The vaccine formulation of claim 14 or 15 , further comprising one or both of:
a fourth isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 9 or comprising the amino acid sequence of SEQ ID NO: 9 lacking 1-3 amino acids from the N-terminus, C-terminus, or both; and
a fifth isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or comprising the amino acid sequence of SEQ ID NO: 10 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.

17. The vaccine formulation of claim 16 , wherein the fifth polypeptide is lipidated.

18. A vaccine formulation comprising:
a pharmaceutically acceptable carrier;
an effective amount of an adjuvant;
a first isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 265, 266, or 268 or comprising the amino acid sequence of SEQ ID NO: 265, 266, or 268 lacking 1-3 amino acids from the N-terminus, C-terminus, or both;
a second isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 9 or comprising the amino acid sequence of SEQ ID NO: 9 lacking 1-3 amino acids from the N-terminus, C-terminus, or both; and
a third isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or comprising the amino acid sequence of SEQ ID NO: 10 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.

19. The vaccine formulation of claim 18 , wherein the third polypeptide is lipidated.

20. A vaccine formulation comprising:
a pharmaceutically acceptable carrier;
an effective amount of an adjuvant;
a first isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 265 or comprising the amino acid sequence of SEQ ID NO:265 lacking 1-3 amino acids from the N-terminus, C-terminus, or both;
a second isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 6 or comprising the amino acid sequence of SEQ ID NO:6 lacking 1-3 amino acids from the N-terminus, C-terminus, or both;
a third isolated polypeptide comprising the amino acid sequence of SEQ ID NO:7 or comprising the amino acid sequence of SEQ ID NO:7 lacking 1-3 amino acids from the N-terminus, C-terminus, or both;
a fourth isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 9 or comprising the amino acid sequence of SEQ ID NO: 9 lacking 1-3 amino acids from the N-terminus, C-terminus, or both; and
a fifth isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or comprising the amino acid sequence of SEQ ID NO: 10 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.

21. The vaccine formulation of claim 20 , wherein the adjuvant is alum.

22. The vaccine formulation of claim 20 , wherein the vaccine formulation comprises 1-1000 μg of each polypeptide.

23. The vaccine formulation of any one of claim 1 , 5 , 14 , 18 , or 20 , wherein upon administration to a subject, the vaccine formulation induces an immune response against S. pneumoniae.

24. A pharmaceutical composition comprising:
a pharmaceutically acceptable carrier;
an effective amount of an adjuvant;
a first isolated polypeptide comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:265, 266, or 268, or comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:265, 266, or 268 lacking 1-3 amino acids from the N-terminus, C-terminus, or both; and
a second isolated polypeptide comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:9 or 10, or comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:9 or 10 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.

25. The pharmaceutical composition of claim 24 , further comprising a third isolated polypeptide comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:6 or 7, or comprising an amino acid sequence at least 98% identical to the amino acid sequ

Assignees

• Gierahn Todd
• Malley Richard
• Genocea Biosciences Inc
• Childrens Medical Center

Inventors

• Gierahn Todd
• Malley Richard

Classifications

• A61K39/02 Primary

  Bacterial antigens · CPC title

• A61K39/092 Primary

  Streptococcus · CPC title

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61K2039/55505

  Inorganic adjuvants · CPC title

• A61P31/04

  Antibacterial agents · CPC title